Literature DB >> 11753166

Serum biotinidase activity in children with chronic liver disease and its clinical significance.

Aysun Pabuçcuoğlu1, Sema Aydoğdu, Meral Baş.   

Abstract

BACKGROUND: Biotinidase is the enzyme responsible for liberating the vitamin biotin from biocytin and dietary protein-bound vitamin. Individuals lacking biotinidase activity become biotin deficient. Because the liver is the major source of plasma biotinidase, chronic liver diseases can lead to decreased serum biotinidase activity and biotin deficiency. The aim of this study is to determine serum biotinidase activity values in children with chronic liver disease and to investigate the relation among enzyme activity, certain liver function tests, and degree of liver damage.
METHOD: In this study, using a spectrophotometric method, biotinidase activity was determined in sera from 62 children with chronic liver diseases (median age, 9.73 years; range, 8 months to 18 years) and from 27 healthy controls. Diagnoses of the patient group were as follows: noncirrhotic chronic hepatitis B virus infection (n = 12), metabolic liver diseases (n = 16), autoimmune hepatitis (n = 6), intrahepatic and extrahepatic cholestasis (n = 14), fulminant hepatitis (n = 5), cryptogenic cirrhosis n = 5), prehepatic portal hypertension (n = 4). Meanwhile, serum albumin, total bilirubin, alkaline phosphatase, alanine aminotransferase, and gamma-glutamyltransferase concentrations and prothrombine time were determined for each patient and the results were correlated with serum biotinidase activity.
RESULTS: There was significant difference between mean enzyme activity of the controls (7.6 +/- 1.2 nmol x min(-1) x mL(-1)) and of all patients with chronic liver disease (6.3 +/- 2.5 nmol x min(-1) x mL(-1)) ( P < 0.05). Serum biotinidase activity in patients with noncirrhotic chronic liver diseases (chronic viral hepatitis, prehepatic portal hypertension, glycogen storage disease, Gaucher disease) was within the normal ranges. However, serum biotinidase activity in patients with cirrhosis and Wilson disease was significantly less than that of the control group ( P < 0.05). The lowest enzyme activities were detected in patients with fulminant hepatitis.
CONCLUSION: In this study, serum biotinidase activity was significantly lower in patients with cirrhosis, particularly in the patients with decompensated cirrhosis and fulminant hepatitis who exhibited no clinical symptoms related to biotin deficiency. The decreased serum biotinidase activity in chronic liver diseases was associated with severe impairment of hepatocellular function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753166     DOI: 10.1097/00005176-200201000-00014

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

1.  Evaluation of the biotinidase activity in hepatic glycogen storage disease patients. Undescribed genetic finding associated with atypical enzymatic behavior: an outlook.

Authors:  Celia J Angaroni; Alicia N Giner-Ayala; Lorena P Hill; Norberto B Guelbert; Ana E Paschini-Capra; Raquel Dodelson de Kremer
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Elevated serum biotinidase activity in hepatic glycogen storage disorders--a convenient biomarker.

Authors:  P Paesold-Burda; M R Baumgartner; R Santer; N U Bosshard; B Steinmann
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

3.  Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients.

Authors:  Paula B M Luís; Jos P Ruiter; Lodewijk IJlst; Luísa Diogo; Paula Garcia; Isabel Tavares de Almeida; Marinus Duran; Ronald J Wanders; Margarida F B Silva
Journal:  J Inherit Metab Dis       Date:  2011-12-22       Impact factor: 4.982

Review 4.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

5.  Biotin and biotinidase deficiency.

Authors:  Janos Zempleni; Yousef I Hassan; Subhashinee Sk Wijeratne
Journal:  Expert Rev Endocrinol Metab       Date:  2008-11-01

6.  Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics.

Authors:  Erin T Strovel; Tina M Cowan; Anna I Scott; Barry Wolf
Journal:  Genet Med       Date:  2017-07-05       Impact factor: 8.822

7.  Beyond predicting diagnosis: Is there a role for measuring biotinidase activity in liver glycogen storage diseases?

Authors:  Areeg El-Gharbawy; Adviye A Tolun; Carine A Halaby; Stephanie L Austin; Priya S Kishnani; Deeksha S Bali
Journal:  Mol Genet Metab Rep       Date:  2022-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.